Treatment and Prevention of Secondary CNS Lymphoma

ABSTRACT

Central nervous system (CNS) involvement in non-Hodgkin lymphoma is a serious, potentially preventable complication that can occur in 5 to 10% of patients. Its occurrence is directly correlated with pathologic aggressiveness and ranges from less than 3% in the indolent, less-aggressive histologies to as high as 50% in the very aggressive ones such as Burkitt lymphoma. Aggressive treatment once detected can improve neurologic outcome, but because it is often associated with contemporaneous systemic relapse, is rarely associated with long-term survival. Preventing its occurrence, therefore, remains an important goal of initial treatment. Despite there being some suggestive evidence that the addition of systemic rituximab and several intracerebrospinal fluid chemotherapy regimens may have decreased the incidence of CNS involvement, both optimal selection of those patients who should receive prophylaxis as well as the best prophylactic regimen remain active areas of investigation.

KEYWORDS

Secondary CNS lymphoma - non-Hodgkin lymphoma - cerebrospinal fluid - CNS prophylaxis

REFERENCES

• 1 Horner MJRL, Krapcho M, Neyman N, et al SEER Cancer Statistics Review, 1975–2006. Bethesda, MD; National Cancer Institute 2009
• 2 Colocci N, Glantz M, Recht L. Prevention and treatment of central nervous system involvement by non-Hodgkin's lymphoma: a review of the literature.  Semin Neurol. 2004;  24(4) 395-404
• 3 Haioun C, Besson C, Lepage E et al.. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des Lymphomes de l'Adulte.  Ann Oncol. 2000;  11(6) 685-690
• 4 Hollender A, Kvaloy S, Nome O, Skovlund E, Lote K, Holte H. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model.  Ann Oncol. 2002;  13(7) 1099-1107
• 5 Tomita N, Kodama F, Sakai R et al.. Predictive factors for central nervous system involvement in non-Hodgkin's lymphoma: significance of very high serum LDH concentrations.  Leuk Lymphoma. 2000;  38(3-4) 335-343
• 6 van Besien K, Ha C S, Murphy S et al.. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma.  Blood. 1998;  91(4) 1178-1184
• 7 Bernstein S H, Unger J M, Leblanc M, Friedberg J, Miller T P, Fisher R I. Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 — the Southwest Oncology Group.  J Clin Oncol. 2009;  27(1) 114-119
• 8 Jaffe ESHN, Stein H, Vardiman JW Pathology and genetics of tumours of haematopoietic and lymphoid tissues. In: World Health Organization Classification of Tumours. Lyon, France; IARC Press 2001
• 9 Hiddemann W, Longo D L, Coiffier B et al.. Lymphoma classification—the gap between biology and clinical management is closing.  Blood. 1996;  88(11) 4085-4089
• 10 Seki R, Ohshima K, Nagafuji K et al.. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Japan: a retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group.  Int J Hematol. 2010;  91(2) 258-266
• 11 Boehme V, Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).  Blood. 2009;  113(17) 3896-3902
• 12 Villa D, Connors J M, Shenkier T N et al.. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy.  Ann Oncol. 2010;  21(5) 1046-1052
• 13 Lim H Y, Thiel E, Glantz M J. To protect and defend: central nervous system prophylaxis in patients with non-Hodgkin's lymphoma.  Curr Opin Oncol. 2008;  20(5) 495-501
• 14 Recht L, Straus D J, Cirrincione C, Thaler H T, Posner J B. Central nervous system metastases from non-Hodgkin's lymphoma: treatment and prophylaxis.  Am J Med. 1988;  84(3 Pt 1) 425-435
• 15 Hegde U, Filie A, Little R F et al.. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology.  Blood. 2005;  105(2) 496-502
• 16 Glantz M J, Cole B F, Glantz L K et al.. Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results.  Cancer. 1998;  82(4) 733-739
• 17 Finn W G, Peterson L C, James C, Goolsby C L. Enhanced detection of malignant lymphoma in cerebrospinal fluid by multiparameter flow cytometry.  Am J Clin Pathol. 1998;  110(3) 341-346
• 18 Bromberg J E, Breems D A, Kraan J et al.. CSF flow cytometry greatly improves diagnostic accuracy in CNS hematologic malignancies.  Neurology. 2007;  68(20) 1674-1679
• 19 Brem S S, Bierman P J, Black P et al.. Central nervous system cancers.  J Natl Compr Canc Netw. 2008;  6(5) 456-504
• 20 Zeiser R, Burger J A, Bley T A, Windfuhr-Blum M, Schulte-Mönting J, Behringer D M. Clinical follow-up indicates differential accuracy of magnetic resonance imaging and immunocytology of the cerebral spinal fluid for the diagnosis of neoplastic meningitis—a single centre experience.  Br J Haematol. 2004;  124(6) 762-768
• 21 Strik H MPP, Pilgram-Pastor S, Buhk J H. Neoplastic meningitis—Is MRI as sensitive as CSF cytology?. Paper presented at: 2009 ASCO Annual Meeting May 29–June 2, 2009 Orlando, FL;
• 22 Su C S, Lan M Y, Chang Y Y, Lin W C, Liu K T. Clinical features, neuroimaging and treatment of spontaneous intracranial hypotension and magnetic resonance imaging evidence of blind epidural blood patch.  Eur Neurol. 2009;  61(5) 301-307
• 23 Chamberlain M C, Glantz M, Groves M D, Wilson W H. Diagnostic tools for neoplastic meningitis: detecting disease, identifying patient risk, and determining benefit of treatment.  Semin Oncol. 2009;  36(4, Suppl 2) S35-S45
• 24 Kara I O, Sahin B, Gunesacar R. Levels of serum and cerebrospinal fluid soluble CD27 in the diagnosis of leptomeningeal involvement of hematolymphoid malignancies.  Adv Ther. 2007;  24(4) 741-747
• 25 Stockhammer G, Poewe W, Burgstaller S et al.. Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis.  Neurology. 2000;  54(8) 1670-1676
• 26 Roy S, Josephson S A, Fridlyand J et al.. Protein biomarker identification in the CSF of patients with CNS lymphoma.  J Clin Oncol. 2008;  26(1) 96-105
• 27 Zetterberg H, Andreasson U, Blennow K. CSF antithrombin III and disruption of the blood-brain barrier.  J Clin Oncol. 2009;  27(13) 2302-2303, author reply 2303–2304
• 28 Glantz M J, Hall W A, Cole B F et al.. Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status.  Cancer. 1995;  75(12) 2919-2931
• 29 Brugières L, Le Deley M C, Rosolen A et al.. Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group.  J Clin Oncol. 2009;  27(6) 897-903
• 30 Grossman S A, Finkelstein D M, Ruckdeschel J C, Trump D L, Moynihan T, Ettinger D S. Eastern Cooperative Oncology Group . Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis.  J Clin Oncol. 1993;  11(3) 561-569
• 31 Glantz M J, LaFollette S, Jaeckle K A et al.. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis.  J Clin Oncol. 1999;  17(10) 3110-3116
• 32 Glantz M J, Van Horn A, Fisher R, Chamberlain M C. Route of intracerebrospinal fluid chemotherapy administration and efficacy of therapy in neoplastic meningitis.  Cancer. 2010;  116(8) 1947-1952
• 33 Liu C Y, Teng H W, Lirng J F, Chiou T J, Chen P M, Hsiao L T. Sustained remission and long-term survival of secondary central nervous system involvement by aggressive B-cell lymphoma after combination treatment of systemic high-dose chemotherapy and intrathecal rituximab.  Leuk Lymphoma. 2008;  49(10) 2018-2021
• 34 Villela L, García M, Caballero R, Borbolla-Escoboza J R, Bolaños-Meade J. Rapid complete response using intrathecal rituximab in a patient with leptomeningeal lymphomatosis due to mantle cell lymphoma.  Anticancer Drugs. 2008;  19(9) 917-920
• 35 Antonini G, Cox M C, Montefusco E et al.. Intrathecal anti-CD20 antibody: an effective and safe treatment for leptomeningeal lymphoma.  J Neurooncol. 2007;  81(2) 197-199
• 36 Glantz M J, Jaeckle K A, Chamberlain M C et al.. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors.  Clin Cancer Res. 1999;  5(11) 3394-3402
• 37 Rubenstein J L, Fridlyand J, Abrey L et al.. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma.  J Clin Oncol. 2007;  25(11) 1350-1356
• 38 Pui C H, Thiel E. Central nervous system disease in hematologic malignancies: historical perspective and practical applications.  Semin Oncol. 2009;  36(4, Suppl 2) S2-S16
• 39 Kikuchi A, Kawada H, Iwaki Y et al.. [Measurement of rituximab concentration in the cerebrospinal fluid in CNS lymphoma].  Rinsho Ketsueki. 2004;  45(12) 1255-1257
• 40 Harjunpää A, Wiklund T, Collan J et al.. Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma.  Leuk Lymphoma. 2001;  42(4) 731-738
• 41 Arkenau H T, Chong G, Cunningham D et al.. The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma.  Ann Oncol. 2007;  18(3) 541-545
• 42 Boehme V, Zeynalova S, Kloess M German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma—a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).  Ann Oncol. 2007;  18(1) 149-157
• 43 Goedert J J, Coté T R, Virgo P et al.. Spectrum of AIDS-associated malignant disorders.  Lancet. 1998;  351(9119) 1833-1839
• 44 Opelz G, Döhler B. Lymphomas after solid organ transplantation: a collaborative transplant study report.  Am J Transplant. 2004;  4(2) 222-230
• 45 Bihan C L, Chevojon P, Doll J et al.. Change in cause of death before and after introduction of highly active antiretroviral therapy (HAART): three general hospitals based study. Paper presented at: International Conference on AIDS July 7–12, 2002 Barcelona, Spain;
• 46 Tirelli U, Spina M, Vaccher E et al.. Clinical evaluation of 451 patients with HIV related non-Hodgkin's lymphoma: experience on the Italian cooperative group on AIDS and tumors (GICAT).  Leuk Lymphoma. 1995;  20(1-2) 91-96
• 47 Schürmann D DD, Dienemann D, Jautzke G et al.. Malignant lymphomas in HIV-seropositive patients. Frequency, features, and prognosis. Report on 31 cases.  Klin Wochenschr. 1991;  69(15) 679-686
• 48 Robotin M C, Law M G, Milliken S et al.. Clinical features and predictors of survival of AIDS-related non-Hodgkin's lymphoma in a population-based case series in Sydney, Australia.  HIV Med. 2004;  5(5) 377-384
• 49 Diamond C, Taylor T H, Im T, Miradi M, Anton-Culver H. Improved survival and chemotherapy response among patients with AIDS-related non-Hodgkin's lymphoma receiving highly active antiretroviral therapy.  Hematol Oncol. 2006;  24(3) 139-145
• 50 Palmieri C, Treibel T, Large O, Bower M. AIDS-related non-Hodgkin's lymphoma in the first decade of highly active antiretroviral therapy.  QJM. 2006;  99(12) 811-826
• 51 Navarro J T, Vall-Llovera F, Mate J L, Morgades M, Feliu E, Ribera J M. Decrease in the frequency of meningeal involvement in AIDS-related systemic lymphoma in patients receiving HAART.  Haematologica. 2008;  93(1) 149-150
• 52 Spina M, Chimienti E, Martellotta F et al.. Phase 2 study of intrathecal, long-acting liposomal cytarabine in the prophylaxis of lymphomatous meningitis in human immunodeficiency virus-related non-Hodgkin lymphoma.  Cancer. 2010;  116(6) 1495-1501
• 53 Caillard S, Agodoa L Y, Bohen E M, Abbott K C. Myeloma, Hodgkin disease, and lymphoid leukemia after renal transplantation: characteristics, risk factors and prognosis.  Transplantation. 2006;  81(6) 888-895
• 54 Buell J F, Gross T G, Hanaway M J et al.. Posttransplant lymphoproliferative disorder: significance of central nervous system involvement.  Transplant Proc. 2005;  37(2) 954-955
• 55 Alvarnas J C, Negrin R S, Horning S J et al.. High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma.  Biol Blood Marrow Transplant. 2000;  6(3A, 3A) 352-358
• 56 Bokstein F, Lossos A, Lossos I S, Siegal T. Central nervous system relapse of systemic non-Hodgkin's lymphoma: results of treatment based on high-dose methotrexate combination chemotherapy.  Leuk Lymphoma. 2002;  43(3) 587-593
• 57 Kasamon Y L, Jones R J, Piantadosi S et al.. High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement.  Biol Blood Marrow Transplant. 2005;  11(2) 93-100
• 58 Jahnke K, Thiel E, Martus P, Schwartz S, Korfel A. Retrospective study of prognostic factors in non-Hodgkin lymphoma secondarily involving the central nervous system.  Ann Hematol. 2006;  85(1) 45-50
• 59 Matsumoto Y, Horiike S, Fujimoto Y et al.. Effectiveness and limitation of gamma knife radiosurgery for relapsed central nervous system lymphoma: a retrospective analysis in one institution.  Int J Hematol. 2007;  85(4) 333-337
• 60 Garcia-Marco J A, Panizo C, Garcia E S et al.. Efficacy and safety of liposomal cytarabine in lymphoma patients with central nervous system involvement from lymphoma.  Cancer. 2009;  115(9) 1892-1898
• 61 Chamberlain M C, Johnston S K, Van Horn A, Glantz M J. Recurrent lymphomatous meningitis treated with intra-CSF rituximab and liposomal ara-C.  J Neurooncol. 2009;  91(3) 271-277
• 62 Fischer L, Korfel A, Kiewe P, Neumann M, Jahnke K, Thiel E. Systemic high-dose methotrexate plus ifosfamide is highly effective for central nervous system (CNS) involvement of lymphoma.  Ann Hematol. 2009;  88(2) 133-139
• 63 Chua S L, Seymour J F, Streater J, Wolf M M, Januszewicz E H, Prince H M. Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma.  Leuk Lymphoma. 2002;  43(9) 1783-1788
• 64 Tomita N, Kodama F, Kanamori H, Motomura S, Ishigatsubo Y. Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-hodgkin lymphoma.  Cancer. 2002;  95(3) 576-580
• 65 Tilly H, Lepage E, Coiffier B Groupe d'Etude des Lymphomes de l'Adulte et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.  Blood. 2003;  102(13) 4284-4289
• 66 Feugier P, Virion J M, Tilly H et al.. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab.  Ann Oncol. 2004;  15(1) 129-133